Heartland Advisors Inc. Buys New Stake in Arcturus Therapeutics Holdings Inc. $ARCT

Heartland Advisors Inc. purchased a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the second quarter, Holdings Channel.com reports. The fund purchased 219,300 shares of the biotechnology company’s stock, valued at approximately $1,474,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Osaic Holdings Inc. raised its position in shares of Arcturus Therapeutics by 51.8% in the second quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 738 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after purchasing an additional 2,586 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new position in shares of Arcturus Therapeutics in the 4th quarter valued at about $64,000. Intech Investment Management LLC acquired a new position in Arcturus Therapeutics in the 4th quarter worth about $70,000. Finally, CANADA LIFE ASSURANCE Co raised its holdings in Arcturus Therapeutics by 65.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 12,009 shares of the biotechnology company’s stock worth $73,000 after purchasing an additional 4,737 shares during the period. Institutional investors and hedge funds own 94.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on ARCT shares. Wall Street Zen upgraded Arcturus Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Arcturus Therapeutics Stock Up 22.4%

Shares of NASDAQ ARCT opened at $13.45 on Friday. The firm has a 50-day simple moving average of $7.09 and a 200-day simple moving average of $7.49. The stock has a market capitalization of $382.25 million, a price-to-earnings ratio of -4.06 and a beta of 2.39. Arcturus Therapeutics Holdings Inc. has a 52 week low of $5.50 and a 52 week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.16. The company had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. As a group, equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -3.48 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.